Дата |
---|
11:15 |
07.05.2024 |
06.05.2024 |
03.05.2024 |
02.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.45
|
1.53
|
1.53
|
1.53
|
1.53
|
1.53
|
|
|
|
|
1.45
|
1.55
|
1.63
|
1.63
|
1.63
|
1.63
|
|
|
|
|
1.56
|
1.62
|
1.65
|
1.65
|
1.65
|
1.65
|
|
|
|
|
1.59
|
1.68
|
1.71
|
1.71
|
1.71
|
1.71
|
|
|
|
|
1.62
|
1.70
|
1.81
|
1.81
|
1.81
|
1.81
|
|
|
|
|
1.70
|
1.79
|
1.58
|
1.58
|
1.58
|
1.58
|
|
|
|
|
1.59
|
1.69
|
1.53
|
1.53
|
1.53
|
1.53
|
|
|
|
|
1.47
|
1.52
|
1.54
|
1.54
|
1.54
|
1.54
|
|
|
|
|
1.56
|
1.68
|
1.50
|
1.50
|
1.50
|
1.50
|
|
|
|
|
1.51
|
1.63
|
1.40
|
1.40
|
1.40
|
1.40
|
|
|
|
|
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED lamp, Ameluz-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Показать все Скрыть